A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin e Cancer Prevention Trial (SELECT)

Cancer Prevention Research

Volumn 7, Issue 9, 2014, Pages 950-957

  Martinez, Erin E ^a   Darke, Amy K ^b   Tangen, Catherine M ^b   Goodman, Phyllis J ^b   Fowke, Jay H ^a   Klein, Eric A ^c   Abdulkadir, Sarki A ^a,d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; MESSENGER RNA; NUCLEIC ACID BINDING PROTEIN; PROSTATE SPECIFIC ANTIGEN; SELENIUM; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG; ANTIOXIDANT; HOMEODOMAIN PROTEIN; NKX3-1 PROTEIN, HUMAN; VITAMIN;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; CANCER GRADING; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA BINDING; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; VITAMIN SUPPLEMENTATION; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; ANTIOXIDANTS; CASE-CONTROL STUDIES; GENOTYPE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK FACTORS; TRANSCRIPTION FACTORS; VITAMIN E; VITAMINS;

EID: 84907291916     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0075     Document Type: Article

References (30)

1. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-6.
2. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003;91:608-12.
3. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J Urol 2001;166:1311-5.
4. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005;97:94-102.
5. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549-56.
6. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 1997;43:69-77.
7. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000;60:6111-5.
8. Asatiani E, Huang WX, Wang A, Rodriguez Ortner E, Cavalli LR, Haddad BR, et al. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res. 2005;65:1164-73.
9. Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 2005;65:6773-9.
10. Martinez EE, Anderson PD, Abdulkadir SA. Antioxidant treatment promotes prostate epithelial proliferation in Nkx3.1 mutant mice. PLoS One 2012;7:e46792.
11. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999;13:966-77.
12. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, et al. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 2002;22:1495-503.
13. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, Hayward SW, et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002;62:2999-3004.
14. Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion. Cancer Res 2006;66:10683-90.
15. Khalili M, Mutton LN, Gurel B, Hicks JL, De Marzo AM, Bieberich CJ. Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. Am J Pathol 2010;176:2259-68.
16. Akamatsu S, Takata R, Ashikawa K, Hosono N, Kamatani N, Fujioka T, et al. A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression. Hum Mol Genet 2010;19:4265-72.
17. Gelmann EP, Steadman DJ, Ma J, Ahronovitz N, Voeller HJ, Swope S, et al. Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function. Cancer Res 2002;62:2654-9.
18. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
19. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73:1.
20. Onland-Moret NC, van der A DL, van der Schouw YT, Buschers W, Elias SG, van Gils CH, et al. Analysis of case-cohort data: a comparison of different methods. J Clin Epidemiol 2007;60:350-5.
21. Klein EA. Selenium and vitamin E: interesting biology and dashed hope. J Natl Cancer Inst 2009;101:283-5.
22. Magee JA, Abdulkadir SA, Milbrandt J. Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. Cancer Cell 2003;3:273-83.
23. Mogal AP, van der Meer R, Crooke PS, Abdulkadir SA. Haploinsufficient prostate tumor suppression by Nkx3.1: a role for chromatin accessibility in dosage-sensitive gene regulation. J Biol Chem 2007;282:25790-800.
24. Anderson PD, McKissic SA, Logan M, Roh M, Franco OE, Wang J, et al. Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest 2012;122: 1907-19.
25. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst 2014;106: djt456.
26. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, Erdman JW Jr, et al. Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis 2008;29:2335-40.
27. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005;65:2498-504.
28. Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, et al. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int 2011;107:126-34.
29. Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, et al. Plasma selenium, manganese superoxide dismutase, and intermediate-or high-risk prostate cancer. J Clin Oncol 2009;27:3577-83.
30. Zhang J, Dhakal IB, Greene G, Lang NP, Kadlubar FF. Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: effects modified by plasma antioxidants. Urology 2010;75:779-85.